PROFILBARU.COM

TachoSil
Combination of
Fibrinogen	Glycoprotein
Thrombin	Coagulation factor
Clinical data
Trade names	Tachosil
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Tachosil;
Routes of; administration	Epilesional
ATC code	B02BC30 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
KEGG	D12591;

Tachosil is an equine collagen sponge coated with the human plasma-derived coagulation factors fibrinogen and thrombin.^[2]^[5] It is used during surgery to stop local bleeding on internal organs (hemostasis).^[2] Tachosil reacts upon contact with blood, other body fluids or saline to form a clot that glues it to the tissue surface.^[4]

Tachosil may cause an allergic reaction, thrombosis (blood clots), a blockage in the intestine when used during abdominal surgeries, the formation of scar tissue and foreign body granuloma (a type of inflammatory reaction).^[4]

Medical uses

Tachosil is indicated in for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient.^[4] According to studies comparing Tachosil to argon beamer or stitching in patients undergoing liver surgery, Tachosil was associated with significantly lower time until the bleeding stopped.[1] Tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery.^[4]

References

^ "TachoSil sealant matrix - Summary of Product Characteristics (SmPC)". (emc). 31 January 2020. Archived from the original on 10 July 2020. Retrieved 9 July 2020.
^ ^a ^b ^c "Tachosil- thrombin human and fibrinogen patch". DailyMed. 16 February 2023. Archived from the original on 19 May 2023. Retrieved 19 May 2023.
^ "Tachosil- thrombin human and fibrinogen patch". DailyMed. 2 November 2022. Archived from the original on 19 May 2023. Retrieved 19 May 2023.
^ ^a ^b ^c ^d ^e "TachoSil EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 13 July 2020. Retrieved 9 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ Colombo GL, Bettoni D, Di Matteo S, Grumi C, Molon C, Spinelli D, et al. (2014). "Economic and outcomes consequences of Tachosil: a systematic review". Vascular Health and Risk Management. 10: 569–75. doi:10.2147/VHRM.S63199. PMC 4166367. PMID 25246797.